SGLT2 inhibitors are recommended by the AHA/ACC/HFSA for patients with symptomatic chronic HFrEF, irrespective of the presence of type 2 diabetes. In two clinical trials, the addition of the SGLT2 inhibitors dapagliflozin and empagliflozin to standard therapies for patients with HFrEF resulted in ~25% relative risk reduction of the primary endpoints of worsening heart failure, cardiovascular death, or hospitalization for heart failure.
SGLT2 inhibitors have also been shown to improve renal outcomes. However, it's important to note that SGLT2 inhibitors have been shown to increase the risk for diabetic ketoacidosis in patients with type 2 diabetes.
Learn more about the treatment of HFrEF.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Alanna Morris, Michael Weber, Jeffrey J. Hsu. Fast Five Quiz: Heart Failure With Reduced Ejection Fraction (HFrEF) Treatment Optimization - Medscape - Nov 16, 2023.